- Home
- » Tags
- » Sebelipase alfa
Top View
- GPI Class 30 – Endocrine and Metabolic Agents, Miscellaneous Review Time Frame: 11/2015 – 04/2017 Previous Class Review: 02/2016
- Covering Gene Therapy, Somatic Cell Therapy), and Recombinant Proteins Other Than Monoclonal Antibodies
- Pediatric Orphan Drug Indications: 2010–2018 Lauren Kimmel, BS,A Rena M
- Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
- 5.01.576 Drugs for Rare Diseases
- Partnerre Trigger Pharmaceuticals (At 5.21.21) Code Brand Name Generic Name Code Brand Name Generic Name J3590 Abecma®
- Sebelipase Alfa As Enzyme Replacement Therapy in Three
- 57 Orphan Drugs Approved by the EC Between 2012 and 2016 Were Found, of Which 40 (70.2%) Had Been Authorised in Spain
- Partnerre Trigger Pharmaceuticals (At 2.6.20)
- Reimbursement Criteria for Frequently Requested Drugs
- Rare Dyslipidaemias, from Phenotype to Genotype to Management: a European Atherosclerosis Society Task Force Consensus Statement
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- New Drugs Reviewed by CPG May 16, 2016
- Enzyme Related Therapies
- Corporate Medical Policy
- New Brunswick Drug Plans Formulary
- Environmental Assessment
- Lysosomes As a Therapeutic Target
- Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders
- Mandatory Specialty Drug List
- Kanuma, INN-Sebelipase Alfa
- The Basics Of
- A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency
- Abbreviated Criteria
- Embargoed Until 6:30 P.M. Et on Monday, October 12, 2015
- Specialty Drug List
- AHFS Pharmacologic-Therapeutic Classification System
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Nhs-England-Drugs-List-V14.1.Pdf
- Medimpact April 2019 Specialty Drug List
- Prior Authorization — Premium
- Poster Session Abstracts
- Complement Inhibitor and Enzyme/Protein Replacement Therapy
- View the Specialty Pharmacy 1199 SEIU Drug List
- [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
- Supplementary Table 1: New Active Substances Approved by EMA Or FDA Initially in 2014-2016, with Approval Date Tracked Until 2017
- Orphan Drugs in the United States Providing Context for Use and Cost
- Do Not Tube List
- Specialty Pharmacy Drug List Specialty Medications List
- Unitedhealthcare Oxford
- View Annual Report
- Management of Genetic Diseases: Present and Future
- 5PSQ-007 Sebelipase Alfa As Enzyme Replacement Therapy in Three
- Annual Report 2015 Annexes
- Platforms for Production of Protein-Based Vaccines: from Classical to Next-Generation Strategies